Immunomodulatory markers and therapies for the management of infant respiratory syncytial virus infection

The human respiratory syncytial virus (hRSV) is one of childhood diseases' most common respiratory pathogens and is highly associated with lower respiratory tract infections. The dramatic peak in disease that this single-stranded negative-sense RNA virus can elicit during outbreaks is often a significant burden for healthcare systems worldwide. Despite the recent approval of treatments against this virus, this pathogen remains one the most common causative agent of infant mortality around the world.